Sometimes life events may result in your inability to obtain factor for treating hemophilia. If that happens, you can count on the long-standing commitment of Wyeth—the only pharmaceutical company that manufactures exclusively recombinant products for both hemophilia A and hemophilia B. The Wyeth Patient Assistance Program is designed to ensure that eligible patients will receive factor even if they don't have insurance.

Who Is Eligible?
The following criteria determine eligibility:

• You are not covered by public or private health insurance
• You are not eligible for state hemophilia assistance, Medicaid or Medicare, reimbursement, or billing
• You legally reside in the United States
• You have an annual income below $25,000 (single) or below $40,000 (two or more family members)
• You do not have sufficient resources or assistance to pay for the product
• Use of your own assets will cause financial hardship

How It Works

• If you meet the program eligibility guidelines you will be provided up to a maximum of 75,000 IU of product absolutely free
• The Patient Assistance Program is designed for any eligible patient who is factor VIII- or factor IX-deficient
• You do not have to earn, accumulate, track, or redeem points, certificates, or coupons

How to Enroll

• Your health care provider should contact a program administrator (1-888-999-2349; press option 1, then press option 2), who will help evaluate your eligibility to receive BeneFIX or ReFacto at no cost
• An enrollment form, along with instructions and a Patient Authorization Form, will be faxed to the health care provider's office. You should complete and sign this form with your provider
• A program administrator will contact the provider's office if there are any questions and will notify the provider by telephone of your eligibility status
• The amount of product shipped will be determined by the provider's prescription

Indication
BeneFIX is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease), including control and prevention of bleeding in surgical settings. BeneFIX is not indicated for the treatment of other factor deficiencies (eg, factors II, VII, VIII and X) nor the treatment of hemophilia A patients with inhibitors to factor VIII, nor the reversal of coumarin-induced anticoagulation, nor the treatment of bleeding due to low levels of liver-dependent coagulation factors.

Important Safety Information

	•	As with the intravenous administration of any protein product, common adverse reactions may include headache, fever, chills, flushing, nausea, vomiting, or tiredness.
	•	BeneFIX may be contraindicated in patients with a known history of hypersensitivity to hamster protein.
	•	Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported for all factor IX products. Patients should be informed of the early symptoms and signs of hypersensitivity reactions. Patients should discontinue use of the product and contact their health care provider immediately and/or seek emergency care if any hypersensitivity reactions occur.

Please see BeneFIX Prescribing Information

Indication
ReFacto is indicated for the control and prevention of hemorrhagic episodes and for surgical prophylaxis and for short-term routine prophylaxis to reduce the frequency of spontaneous bleeding episodes in patients with hemophilia A. The effect of regular routine prophylaxis on long-term morbidity and mortality is unknown.

Important Safety Information

	•	As with the intravenous administration of any protein product, adverse reactions may include headache, fever, chills, flushing, nausea, vomiting, tiredness, or symptoms of allergic reactions.
	•	The remote possibility exists for hypersensitivity to non-human mammalian proteins. Known hypersensitivity to mouse or hamster proteins may be a contraindication to the use of ReFacto.
	•	Allergic reactions such as hives, itching, difficulty breathing, rapid heart rate, light-headedness and anaphylaxis have been reported for all factor VIII products. Patients should discontinue use of the product and contact their health care provider immediately and/or seek emergency care if any of these symptoms occur.

Please see ReFacto Prescribing Information

The health information contained herein is provided for educational purposes only and is not meant to replace personal discussions between health care providers and patients. All decisions about patient care must be made with a health care provider who can assess the special needs of each individual patient.